비교리스트

 카트 문의
시장보고서
상품코드
1529766

세계의 지혈 밸브 시장 - 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Hemostasis Valve Market Size, Share & Trends Analysis Report By Type, By Application (Angiography, Angioplasty), By End-use, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 110 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

지혈 밸브 시장 규모와 동향

지혈 밸브 세계 시장 규모는 2023년에 1억 7,480만 달러로 추정되며, 2024-2030년에 걸쳐 CAGR 5.8%를 나타낼 것으로 예측됩니다. 심혈관 질환의 유병률 증가, 지지적인 규제 프레임워크, 노인 인구 증가, 기술의 진보가 시장 성장을 크게 촉진하고 있습니다. 세계심장연맹이 2023년에 발표한 보고서에 따르면 심혈관질환(CVD)은 세계적으로 심각한 영향을 미치고 있으며, 세계에서 5억 명 이상이 이환되어 2021년에는 약 2,050만 명 사망했습니다. 이 때문에 혈관조영술이나 혈관성형술과 같은 진단·치료 절차 수요가 높아지고 있으며, 카테터 치료 중에 혈류를 제어하여 환자의 안전을 확보하기 위해서는 지혈 밸브가 필수적입니다.

낮은 침습 절차에 대한 선호도 증가도 시장 성장을 뒷받침하는 중요한 요소입니다. 낮은 침습 절차는 기존의 개복 수술에 비해 통증 완화, 입원 기간 단축, 회복 시간 단축, 합병증 위험 감소 등 수많은 이점을 설명합니다. 그 결과, 이러한 절차를 용이하게 하는 의료기기에 대한 수요가 높아지고 있습니다. 지혈 밸브는 혈류를 정확하게 제어하고 수술 중 누출을 방지하기 위해 카테터를 사용한 낮은 침습 인터벤션에 필수적입니다. 심장 병학 및 기타 의료 부문에서 낮은 침습 기술로의 이동은 지혈 밸브의 채택을 뒷받침하고 있습니다.

세계 인구동태는 출생률 저하와 의료 진보로 인한 평균 수명 연장으로 고령화로 현저하게 변화하고 있습니다. 세계보건기구(WHO)에 따르면 60세 이상 인구는 2050년까지 두배로 늘어나 세계에서 약 21억 명에 달할 것으로 예상됩니다. 이 인구 역학의 변화는 노인에서 심혈관 질환(CVD)을 포함한 노화 관련 질병의 유병률 증가를 강조합니다. 미국 심장협회가 2023년 11월 발표한 논문에 따르면 심부전은 광범위하고 다면적인 심혈관계 질환으로 670만명 이상의 미국인에게 영향을 주며 특히 65세 이상의 노인 사이에 유행하고 있습니다. 심혈관계 질환에 걸리기 쉬운 고령화 사회는 진단·치료 수술 수요를 촉진해, 시장 성장을 견인하고 있습니다.

의료기기의 기술적 진보는 시장 성장을 가속하는데 매우 중요합니다. 재료, 디자인 및 기능의 혁신으로 보다 효과적이고 신뢰할 수 있는 지혈 밸브가 개발되었습니다. 예를 들어 고급 폴리머와 코팅을 사용하면 이러한 장치의 내구성과 생체 적합성이 향상되고 혈전증과 감염과 같은 합병증이 감소합니다. 게다가 사용하기 쉬운 락 기구나 강화된 씰링 능력 등의 새로운 기능을 도입하는 것으로, 임상 현장에 있어서의 지혈 밸브의 효율이 향상하고 있습니다. 예를 들어 Boston Scientific Corporation의 WATCHDOG 지혈 밸브는 누설을 최소화하는 혁신적인 크로스 슬릿 설계를 채택하고 여러 장치를 동시에 수용 할 수있는 8F 루멘을 갖추고 있습니다. 또한, 수술 중 편안함을 높이기 위해 고안된 엄지 받침 기능도 제공합니다. 이러한 디자인 요소는 출혈량과 공기 색전증의 위험을 줄이고 의료 절차 전반에 걸쳐 환자의 안전을 최우선으로 생각합니다.

이러한 기술적 개선은 절차가 보다 안전하고 효율적으로 되고, 지혈 밸브의 채용을 촉진합니다.

세계 지혈 밸브 시장 세분화

이 보고서는 2018-2030년의 수익 성장과 각 하위 부문의 최신 동향 분석을 예측합니다. 이 보고서에서 Grand View Research, Inc.는 세계 지혈 밸브 시장 보고서를 유형, 용도, 최종 용도 및 지역에 따라 세분화합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 지혈 밸브 시장의 변수, 동향, 범위

  • 시장 계통의 전망
    • 상위 시장 전망
    • 보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • COVID-19에 의한 지혈 밸브 시장에 대한 영향
  • 가격 분석

제4장 지혈 밸브 시장 : 유형별, 추정·동향 분석

  • 부문 대시보드
  • 지혈 밸브 시장 : 유형 변동 분석, 2023년과 2030년

제5장 지혈 밸브 시장 : 용도별, 추정·동향 분석

  • 부문 대시보드
  • 지혈 밸브 시장 : 용도 변동 분석, 2023년과 2030년

제6장 지혈 밸브 시장 : 최종 용도별, 추정·동향 분석

  • 부문 대시보드
  • 지혈 밸브 시장 : 최종 용도 변동 분석, 2023년과 2030년

제7장 지혈 밸브 시장 :지역 추정·동향 분석

  • 지역별 시장 점유율 분석, 2023년과 2030년
  • 지역 시장 대시보드
  • 세계 지역 시장 현황
  • 시장 규모와 예측 동향 분석, 2018-2030년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • 기업/경쟁의 분류
  • 벤더 상황
    • 주요 기업의 시장 점유율 분석, 2023년
    • Boston Scientific Corporation
    • Teleflex Incorporated
    • Merit Medical Systems
    • B. Braun Melsungen AG
    • TERUMO CORPORATION
    • Abbott
    • Argon Medical Devices
    • Freudenberg Medical
    • SCW Medicath Ltd
    • Lepu Medical Technology(Beijing) Co.,Ltd.
    • Nipro
    • DeRoyal Industries, Inc.
    • Antmed Corporation
    • Beijing Demax Medical Technology Co
JHS 24.08.21

Hemostasis Valve Market Size & Trends

The global hemostasis valve market size was estimated at USD 174.8 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030. The increasing prevalence of cardiovascular diseases, supportive regulatory frameworks, rising geriatric population, and technological advancements are significantly driving the market growth. According to the report published by World Heart Federation in 2023, cardiovascular diseases (CVDs) have a profound global impact, affecting over half a billion people worldwide and resulting in approximately 20.5 million deaths in 2021.This, in turn, drives the demand for diagnostic and therapeutic procedures like angiography and angioplasty, where hemostasis valves are essential to ensure patient safety by controlling blood flow during catheterization procedures.

The growing preference for minimally invasive procedures is another significant factor propelling the market growth. Minimally invasive techniques offer numerous benefits over traditional open surgeries, including reduced pain, shorter hospital stays, faster recovery times, and lower risk of complications. As a result, there is a heightened demand for medical devices that facilitate these procedures. Hemostasis valves are integral to minimally invasive catheter-based interventions, as they enable precise control of blood flow and prevent leakage during the procedure. The shift towards minimally invasive techniques in cardiology and other medical fields drives the adoption of hemostasis valves.

The global demographic landscape is undergoing a notable shift towards aging, driven by declining birth rates and advancements in healthcare that have prolonged life expectancy. According to the World Health Organization (WHO), the number of people aged 60 years and older is expected to double by 2050, reaching approximately 2.1 billion globally. This demographic transition underscores the increasing prevalence of age-related conditions, including cardiovascular diseases (CVDs) among older adults. According to the article published by the American Heart Association in November 2023, heart failure is a widespread and multifaceted cardiovascular condition impacting more than 6.7 million Americans, particularly prevalent among individuals aged 65 and older. The aging population is susceptibility to cardiovascular diseases drive the demand for diagnostic and therapeutic procedures, driving the market growth.

Technological advancements in medical devices are pivotal in driving the market growth. Materials, design, and functionality innovations have developed more effective and reliable hemostasis valves. For instance, using advanced polymers and coatings has improved the durability and biocompatibility of these devices, reducing complications such as thrombosis and infection. In addition, incorporating novel features such as easy-to-use locking mechanisms and enhanced sealing capabilities has increased the efficiency of hemostasis valves in clinical settings. For instance, the WATCHDOG Hemostasis Valve by Boston Scientific Corporation incorporates an innovative cross-slit design to minimize leakage, complemented by an 8F inner lumen that simultaneously accommodates multiple devices. In addition, it includes a thumb rest feature designed for enhanced comfort during procedures. The design elements collectively contribute to reducing blood loss and the risk of air embolism, prioritizing patient safety throughout medi

cal interventions. These technological improvements ensure that procedures are safer and more efficient, boosting the adoption of hemostasis valves.

Global Hemostasis Valve Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global hemostasis valve market report based on type, application, end-use, and regions.

  • Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Hemostasis Valve Y- Connectors
  • Double Y- Connector Hemostasis Valves
  • One- Handed Hemostasis Valves
  • Others
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Angiography
  • Angioplasty
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

South Korea

Australia

Thailand

  • Latin America

Brazil

Argentina

  • Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hemostasis Valve Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Industry Analysis - Porter's
      • 3.2.3.1. Bargaining power of the suppliers
      • 3.2.3.2. Bargaining power of the buyers
      • 3.2.3.3. Threats of substitution
      • 3.2.3.4. Threats from new entrants
      • 3.2.3.5. Competitive rivalry
    • 3.2.4. PESTEL Analysis
      • 3.2.4.1. Political landscape
      • 3.2.4.2. Economic and Social landscape
      • 3.2.4.3. Technological landscape
  • 3.3. Impact of COVID-19 on the Hemostasis Valve Market
  • 3.4. Pricing Analysis

Chapter 4. Hemostasis Valve Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hemostasis Valve Market: Type Movement Analysis, 2023 & 2030 (USD Million)
    • 4.2.1. Hemostasis Valve Y- Connectors
      • 4.2.1.1. Hemostasis Valve Y- Connectors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Double Y - Connector Hemostasis Valves
      • 4.2.2.1. Double Y - Connector Hemostasis Valves Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3. One-Handed Hemostasis Valves
      • 4.2.3.1. One-Handed Hemostasis Valves Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.4. Others
      • 4.2.4.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hemostasis Valve Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hemostasis Valve Market: Application Movement Analysis, 2023 & 2030 (USD Million)
    • 5.2.1. Angiography
      • 5.2.1.1. Angiography Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Angioplasty
      • 5.2.2.1. Angioplasty Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Angioplasty
      • 5.2.3.1. Angioplasty Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hemostasis Valve Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Hemostasis Valve Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
    • 6.2.1. Hospitals
      • 6.2.1.1. Hospitals Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Ambulatory Surgical Centers
      • 6.2.2.1. Ambulatory Surgical Centers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Other Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hemostasis Valve Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2023
    • 8.3.2. Boston Scientific Corporation
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Type benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Teleflex Incorporated
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Type benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Merit Medical Systems
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Type benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. B. Braun Melsungen AG
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Type benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. TERUMO CORPORATION
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Type benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Abbott
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Type benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Argon Medical Devices
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Type benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Freudenberg Medical
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Type benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. SCW Medicath Ltd
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Type benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Lepu Medical Technology (Beijing)Co.,Ltd.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Type benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Nipro
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Type benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. DeRoyal Industries, Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Type benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Antmed Corporation
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Type benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. Beijing Demax Medical Technology Co
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Type benchmarking
      • 8.3.15.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제